Zosano Pharma logo

ZSAN - Zosano Pharma Share Price

$0.836 0.0  3.0%

Last Trade - 07/05/21

Small Cap
Market Cap £63.8m
Enterprise Value £46.3m
Revenue £160k
Position in Universe 5253rd / 6858
Unlock ZSAN Revenue
Relative Strength (%)
1m -32.7%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -72.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.31 0.000 0.000 0.000 0.000 0.22 3.58 17.8 -6.5%
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, ZosanoPharma Corp revenues increased from $0K to $224K. Net lossdecreased 11% to $33.4M. Revenues reflect an increase indemand for the Company's products and services due tofavorable market conditions. Lower net loss reflectsResearch and development- bal decrease of 15% to $20.9M(expense), General and administrative- bal decrease of 6%to $10.3M (expense), Other income (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ZSAN Revenue Unlock ZSAN Revenue

Net Income

ZSAN Net Income Unlock ZSAN Revenue

Normalised EPS

ZSAN Normalised EPS Unlock ZSAN Revenue

PE Ratio Range

ZSAN PE Ratio Range Unlock ZSAN Revenue

Dividend Yield Range

ZSAN Dividend Yield Range Unlock ZSAN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ZSAN EPS Forecasts Unlock ZSAN Revenue
Profile Summary

Zosano Pharma Corporation is a clinical-stage biopharmaceutical company. The Company is focused on providing systemic administration of therapeutics to patients using its Adhesive Dermally-Applied Microarray (ADAM) technology. ADAM is an intracutaneous delivery system designed to offer drug absorption into the bloodstream. ADAM consists of an array of drug-coated titanium microneedles mounted on an adhesive backing that is pressed on to the skin using a reusable handheld applicator. The Company’s Qtrypta (M207) is a formulation of zolmitriptan delivered utilizing its ADAM technology. Qtrypta (M207) is being investigated as a treatment to provide relief of migraine symptoms in the migraine cycle. The Company has developed its transdermal delivery system to administer novel formulations of existing drugs through the skin for the treatment of a variety of indications.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated January 26, 2012
Public Since January 27, 2015
No. of Shareholders: 11
No. of Employees: 45
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 106,728,371
Free Float (0.0%)
Eligible for
ZSAN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ZSAN
Upcoming Events for ZSAN
Wednesday 12th May, 2021 Estimate
Q1 2021 Zosano Pharma Corp Earnings Release
Thursday 10th June, 2021
Zosano Pharma Corp Annual Shareholders Meeting
Friday 25th June, 2021 Estimate
Zosano Pharma Corp Annual Shareholders Meeting
Wednesday 4th August, 2021 Estimate
Q2 2021 Zosano Pharma Corp Earnings Release
Frequently Asked Questions for Zosano Pharma
What is the Zosano Pharma share price?

As of 07/05/21, shares in Zosano Pharma are trading at $0.836, giving the company a market capitalisation of £63.8m. This share price information is delayed by 15 minutes.

How has the Zosano Pharma share price performed this year?

Shares in Zosano Pharma are currently trading at $0.836 and the price has moved by 11.4% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Zosano Pharma price has moved by -22.32% over the past year.

What are the analyst and broker recommendations for Zosano Pharma?

Of the analysts with advisory recommendations for Zosano Pharma, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Zosano Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Zosano Pharma next release its financial results?

Zosano Pharma is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Zosano Pharma dividend yield?

Zosano Pharma does not currently pay a dividend.

Does Zosano Pharma pay a dividend?

Zosano Pharma does not currently pay a dividend.

When does Zosano Pharma next pay dividends?

Zosano Pharma does not currently pay a dividend.

How do I buy Zosano Pharma shares?

To buy shares in Zosano Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Zosano Pharma?

Shares in Zosano Pharma are currently trading at $0.836, giving the company a market capitalisation of £63.8m.

Where are Zosano Pharma shares listed? Where are Zosano Pharma shares listed?

Here are the trading details for Zosano Pharma:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: ZSAN
What kind of share is Zosano Pharma?

Based on an overall assessment of its quality, value and momentum, Zosano Pharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Zosano Pharma share price forecast 2021?

Shares in Zosano Pharma are currently priced at $0.836. At that level they are trading at 0.16% discount to the analyst consensus target price of 0.00.

Analysts covering Zosano Pharma currently have a consensus Earnings Per Share (EPS) forecast of -0.323 for the next financial year.

How can I tell whether the Zosano Pharma share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zosano Pharma. Over the past six months, the relative strength of its shares against the market has been 0.110k%. At the current price of $0.836, shares in Zosano Pharma are trading at -19.36% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Zosano Pharma PE Ratio?

We were not able to find PE ratio data for Zosano Pharma.

Who are the key directors of Zosano Pharma?

Zosano Pharma's management team is headed by:

Kleanthis Xanthopoulos - IND
Thorsten von Stein - OTH
Eric Scharin - VPR
Joseph Hagan - DRC
John Walker - CHM
Kenneth Greathouse - IND
Steven Elms - IND
Linda Grais - DRC
Dushyant Pathak - SVP
Steven Lo - CEO
Christine Matthews - CFO
Who are the major shareholders of Zosano Pharma?

Here are the top five shareholders of Zosano Pharma based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 3.32% (3.54m shares)
Armistice Capital LLC Hedge Fund
Percentage owned: 2.67% (2.85m shares)
Aisling Capital Management LP Investment Advisor/Hedge Fund
Percentage owned: 2.55% (2.72m shares)
Vanguard Total Stock Market Index Fund Mutual Fund
Percentage owned: 2.4% (2.57m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 1.04% (1.11m shares)
Similar to ZSAN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.